Health
ERS Genomics and Applied StemCell sign agreement on commercialization of CRISPR gene editing tools – News-Medical.net
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of ste…
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.
ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational patents covering CRISPR/Cas9. Companies can obtain licenses to this technology for in…
-
Noosa News12 hours agoChef Sophie Phipps prepares to open restaurant at 30-acre Alsahwa Estate
-
Noosa News23 hours ago‘Miracle cat’ Pablo survives full washing machine cycle on the Gold Coast
-
General10 hours agoHopetoun on WA’s south coast will stop free camping, citing rubbish complaints
-
Business9 hours agoIs this the best ASX 200 share to buy for growth?